Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study - PubMed
3 hours ago
- #SWI/SNF mutations
- #phase II trial
- #EZH2 inhibitor
- Tazemetostat, an EZH2 inhibitor, was studied in a phase II basket trial (NCT02601950) for advanced solid tumors with SWI/SNF mutations.
- The study included 129 patients across five cohorts: malignant rhabdoid tumors (32), synovial sarcoma (33), INI1-negative tumors (32), renal medullary carcinoma (14), and poorly differentiated chordoma (18).
- Primary endpoints were objective responses (CR/PR) or 16-week progression-free survival (PFS), with predefined futility thresholds for each cohort.
- Responses were observed in malignant rhabdoid tumors (9%), INI1-negative tumors (9%), and poorly differentiated chordoma (6%), but not in synovial sarcoma or renal medullary carcinoma.
- Grade ≥3 treatment-related adverse events occurred in 10% of patients.
- The study suggests tazemetostat has preliminary antitumor activity in some poor-prognosis cancers, but combination strategies may be needed for broader efficacy.
- Multiple authors disclosed conflicts of interest, including advisory roles, research funding, and patents related to pharmaceutical companies.